NextPlat healthcare unit wins prescription fulfillment contract
NextPlat Corp (NASDAQ: NXPL, NXPLW) announced that its PharmcoRx subsidiary has been awarded a multi-state prescription fulfillment services contract from virtual healthcare provider DevotedDOc.
The exclusive agreement will begin with prescription fulfillment services for patients in Florida and Georgia in November. NextPlat stated it is working to expand the services nationally, as PharmcoRx holds non-resident pharmacy licenses in Arizona, Colorado, Connecticut, Illinois, Minnesota, Nevada, New Jersey, New York, Pennsylvania, Texas, and Utah.
DevotedDOc operates as a virtual medical group providing urgent care and Medication-Assisted Treatment for opioid use disorder, along with compounded alternatives to GLP-1 medications including semaglutide and tirzepatide for weight loss and hormone replacement therapy. The company serves patients virtually nationwide and maintains physical clinic locations in Florida, Oklahoma, New Mexico, and Georgia.
"We are proud to be selected to support DevotedDOc in their efforts to treat all those suffering from significant health challenges ranging from opioid addiction to obesity," said Birute Norkute, Vice President of Healthcare Operations at NextPlat.
NextPlat describes itself as a global consumer products and services company providing healthcare and technology solutions through e-commerce and retail channels. The company operates an e-commerce communications division offering voice, data, tracking, and IoT products and services, as well as pharmacy and healthcare data management services in the United States through its Progressive Care subsidiary.
The information is based on a company press release statement.
You May Also Be Interested In
- American Resources gets second Nasdaq notice for late SEC filing
- FDA approves Revolution Medicines' daraxonrasib for pancreatic cancer
- Cycurion sets 1-for-8 reverse stock split effective Aug. 28
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share